Hi slura,
I carried out a qualitative analysis on AHZ in October if you are still doing due diligence on the company. I also agree with the content of Purple's post, although I don't expect any CR will be required before Q2/2013.
Revenue growth for the medical device business is looking healthy, and we can probably expect to be a little spoilt with some positive news flow over the next 6+ months, including the announcement of more cardiothoracic surgeons currently seeking authorisation to use CardioCel, and of course the highly anticipated phaseI clinical trial for Prof. Frazer's HSV-2 vaccine. This is the one for investors to watch imo, as there are over 500 million people in the world effected with this virus with no effective treatment available. Pre-clinical data presented last year have also got opinion leaders confident that the same results will be translated into humans, offering prophylactic protection, and a potential cure for those infected by the virus.
500 million people + Social Media = a great investment opportunity. Imo
The CSIRO partnership for stem cell research could be a dark horse, although this collaboration is only at the very early stages of the study cycle.
Plenty of reading material here for you. enjoy.
Allied Health Group - Qualitative Analysis
- Forums
- ASX - By Stock
- biotech thread - wednesday 31st october
Hi slura,I carried out a qualitative analysis on AHZ in October...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online